Melanoma - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Adjuvant

Adjuvant
Protocol Administration at chemotherapy unit level Review Date
Melanoma adjuvant dabrafenib and trametinib Low August 2022
Melanoma adjuvant nivolumab (flat dosing) Low February 2021
Melanoma adjuvant nivolumab (weight based dosing) Low August 2022
Melanoma adjuvant pembrolizumab Low August 2022

Metastatic

Metastatic
Protocol Administration at chemotherapy unit level Review Date
Melanoma metastatic binimetinib and encorafenib Low August 2022
Melanoma metastatic cobimetinib and vemurafenib Low August 2021
Malignant melanoma metastatic dabrafenib and trametinib Low August 2022
Melanoma metastatic ipilimumab Low August 2022
Melanoma metastatic ipilimumab and nivolumab (induction) Medium August 2022
Metastatic nivolumab maintenance (weight based dosing) following ipilimumab and nivolumab Low August 2022
Metastatic nivolumab maintenance (flat dosing) following ipilimumab and nivolumab Low August 2022
Advanced, metastatic or recurrent pembrolizumab
Low February 2022
Advanced or Metastatic nivolumab (flat dosing) Low August 2021
Advanced or Metastatic nivolumab (weight based dosing) Low August 2021

Non-melanoma

Non-melanoma
Protocol Administration at chemotherapy unit level Review Date
Basal cell carcinoma locally advanced or metastatic sonidegib Low August 2025
Basal cell carcinoma locally advanced or metastatic vismodegib Low August 2025
Cutaneous squamous cell carcinoma locally advanced or metastatic cemiplimab
Medium August 2022
Merkel cell carcinoma metastatic avelumab Medium August 2023

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.